AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

The federal Food & Drug Administration has approved two new Alzheimer’s medications that can offer people more time to live ...

ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to ...

Australia is unlikely to follow the UK’s lead in formalising a ban on the use of puberty blockers for young people with ...

The United Kingdom has announced an indefinite ban on the use of puberty blockers for people under 18 with gender dysphoria, ...

Personalised vaccines being trialled for bowel cancer patients are a "really big advance", a senior consultant at a leading ...

The ability of artificial intelligence to quickly analyse huge data sets is revolutionising expensive and time-consuming ...

IQVIA has better operating margins, operational efficiency, strong cash flows, and moderate leverage. See why IQV stock is a ...

An investigation published by The BMJ today raises new concerns over the landmark clinical trial (PLATO) that was used to gain worldwide approval for the anti-platelet drug ticagrelor (Brilinta in the ...

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung ...

Cardiff Oncology plans to share additional clinical data from its onvansertib trial in the first half of 2025.

A new clinical study being done at UCSF could change the way doctors treat patients with traumatic brain injuries.